Advancing Rheumatology Care Through Research

The UCLA Division of Rheumatology coducts innovative biomedical and health-related research studies to advance the understanding and treatment of rheumatic diseases. This research is an essential part of our mission to improve care, discover new therapies, and better understand the conditions we treat. Our researchers are supported by the National Institutes of Health (NIH), non-profit organizations, and industry partners.

Our research includes both interventional (treatment-based) and observational studies. 

  • Interventional studies (also called clinical trials) assign participants to a treatment or therapy to evaluate its effectiveness and outcomes.
  • Observational studies monitor participants in a non-interventional setting to better understand health conditions and disease progression.

Learn More About Clinical Research

Interested in learning more about what it means to take part in a clinical research study? Visit our Clinical Research FAQ page for answers to common questions.


Rheumatology Research Opportunities

We regularly update this page with clinical trials organized by condition. To learn more about participating, please contact our clinical research team at the phone number listed with each trial below.

Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD)

Current Clinical Trials
Current Obervational Studies

Study Type: Observational

Details: CTD-ILD Registry: Any patient with a CTD-ILD.

For more information contact 310-794-2466.

Principal Investigator(s): Elizabeth Volkmann, MD, MS


Study Type: Observational

Details: PET study of 68Ga-FAPi-46 in patients with interstitial lung disease: An exploratory biodistribution study with histopathology validation: This study aims to explore a novel radiographic assessment measure of fibroblast activation in patients with interstitial lung disease. The results may help us better understand the cause of interstitial lung disease and help us in making informed treatment decisions for patients. All patients with interstitial lung disease are eligible to participate.

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS

Upcoming Clinical Trials

There are no upcoming trials for this condition at this time. Please check back for future updates.

 

Upcoming Observational Studies

There are no upcoming observational studies for this condition at this time. Please check back for future updates.

Gout

Current Clinical Trials

Study Type: Treatment/Interventional

Details: Pegloticase: Recapturing immune tolerance to Pegloticase for the management of tophaceous gout.

For more information contact 310-825-9956.

Principal Investigator(s): John FitzGerald, MD, PhD, MBA


Study Type: Treatment/Interventional

Details: UR+AIMS Gout Wearable Skin Uric Acid Monitor Study

For more information contact 310-825-9956.

Principal Investigator(s): John FitzGerald, MD, PhD, MBA

Current Observational Studies

Study Type: Observational

Details: Transitions in Gout Research Study (TIGER) Study

For more information contact 310-825-9956.

Principal Investigator(s): John FitzGerald, MD, PhD, MBA

Upcoming Clinical Trials

There are no upcoming trials for this condition at this time. Please check back for future updates.

Upcoming Observational Studies

There are no upcoming observational studies for this condition at this time. Please check back for future updates.

Myositis

Current Clinical Trials

Study Type: Treatment/Interventional

Details: Pfizer C0251006: A study to evaluate the efficacy and safety of PF06823859 in participants with active idiopathic inflammatory myopathies (including participants with active dermatomyositis or polymyositis).

For more information contact 310-206-4007.

Principal Investigator(s):Christina Charles-Schoeman, MD, MS

Current Observational Studies

Study Type: Observational

Details: HDL: Evaluation of HDL function in patients with and without rheumatic disease.

For more information contact 310-206-4007.

Principal Investigator(s): Christina Charles-Schoeman, MD, MS


Study Type: Observational

Details: Longitudinal Cohort Study of Patients with Idiopathic Inflammatory Myopathies

For more information contact 310-206-4007.

Principal Investigator(s): Christina Charles-Schoeman, MD, MS

Upcoming Clinical Trials

There are no upcoming clinical trials for this condition at this time. Please check back for future updates.

Upcoming Observational Studies

There are no upcoming observational studies for this condition at this time. Please check back for future updates.

Psoriatic Arthritis & Ankylosing Spondylitis

Current Clinical Trials

We are not currently enrolling trials for this condition. Please check back for future updates.

Current Observational Studies

We are not currently enrolling observational studies for this condition. Please check back for future updates.

Upcoming Clinical Trials

There are no upcoming trials for this condition at this time. Please check back for future updates.

Upcoming Observational Studies

There are no upcoming observational studies for this condition at this time. Please check back for future updates.

Rheumatoid Arthritis

Current Clinical Trials

Study Type: Treatment/Interventional

Details: ACTHAR: Use of ACTHAR in Rheumatoid Arthritis Related Flares.

For more information, contact 310-825-9956.

Principal Investigator(s): Veena K. Ranganath, MD, MS, RhMSUS


Study Type: Treatment/Interventional

Details: RA-PROPR: A real-world comparative effectiveness trial of treatment strategies in patients with rheumatoid arthritis: The RA-PRO Pragmatic Trial (RA-PROPR).

For more information, contact 310-825-9956.

Principal Investigator(s): Veena K. Ranganath, MD, MS, RhMSUS

Current Observational Studies

Study Type: Observational

Details: Longitudinal Cardiovascular Risk Study of Patients with Rheumatoid Arthritis.

For more information contact 310-206-4007.

Principal Investigator(s): Christina Charles-Schoeman, MD, MS


Study Type: Observational

Details: CANNABIS: Cannabis Anonymous Questionnaire in UCLA Rheumatology Patients.

For more information, contact 310-825-9956.

Principal Investigator(s): Veena K. Ranganath, MD, MS, RhMSUS

Upcoming Clinical Trials

There are no upcoming trials for this condition at this time. Please check back for future updates.

Upcoming Observational Studies

There are no upcoming observational studies for this condition at this time. Please check back for future updates.

Scleroderma

Current Clinical Trials

Study Type: Treatment/Interventional

Details: A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis: The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo.

For more information contact 310-825-9682.

Principal Investigator(s): Suzanne Kafaja, MD


Study Type: Treatment/Interventional

Details: Cumberland: A Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Systemic Sclerosis Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.

For more information contact 310-825-9682.

Principal Investigator(s): Suzanne Kafaja, MD


Study Type: Treatment/Interventional

Details: EHP-101: A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients With Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101.

For more information contact 310-825-9682.

Principal Investigator(s): Suzanne Kafaja, MD


Study Type: Treatment/Interventional

Details: eSScape: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis.

For more information contact 310-825-9682.

Principal Investigator(s): Suzanne Kafaja, MD


Study Type: Treatment/Interventional

Details: TibuSURE: A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Systemic Sclerosis.

For more information contact 310-825-9682.

Principal Investigator(s): Suzanne Kafaja, MD


Study Type: Treatment/Interventional

Details: BLISSc-ILD: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD).

For more information contact 310-825-9682 or 310-794-1638.

Principal Investigator(s): Suzanne Kafaja, MD, Elizabeth Volkmann, MD, MS


Study Type: Treatment/Interventional

Details: 1366-0031: A study in people With systemic sclerosis to test whether Avenciguat (BI 685509) has an effect on lung function and other systemic sclerosis symptoms (VITALISScE™).

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS


Study Type: Treatment/Interventional

Details: aTyr EFZO-CONNECT: Study to evaluate the efficacy, safety, and tolerability of Efzofitimod in patients with systemic sclerosis (SSc)-related interstitial lung disease (ILD) (SSc-ILD).

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS


Study Type: Treatment/Interventional

Details: Investigating Molecular and Metabolic Signatures in Systemic Sclerosis

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS


Study Type: Treatment/Interventional

Details: PR200-104: Phase 2 safety and efficacy study of Tulisokibart (MK-7240/PRA023) in subjects with systemic sclerosis associated with interstitial lung disease (SSc-ILD) (MK-7240-007) (ATHENA-SSc-ILD).

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS

Current Observational Studies

Study Type: Observational

Details: GRASP: Genome Research in African American Scleroderma Patients (GRASP).

For more information contact 310-825-9682.

Principal Investigator(s): Suzanne Kafaja, MD


Study Type: Observational

Details: Skin Immune Response and Inflammation: Database and tissue bank aimed at evaluating differences in immune response in health and autoimmunity.

For more information contact 310-825-9682.

Principal Investigator(s): Suzanne Kafaja, MD


Study Type: Observational

Details: SPIN: The Scleroderma Patient-Centered Intervention Network (SPIN) cohort collecting data on a regular basis related to problems likely to be important for many people living with scleroderma.

For more information contact 310-825-9682.

Principal Investigator(s): Suzanne Kafaja, MD


Study Type: Observational

Details: Validation of Musculoskeletal Ultrasound in Sclerosis Patients

For more information contact 310-825-9682.

Principal Investigator(s): Suzanne Kafaja, MD


Study Type: Observational

Details: Biomarkers to Predict Treatment Response in Systemic Sclerosis-Interstitial Lung Disease: This is an NIH-sponsored study to discover novel biomarkers that predict response to therapy and outcomes in patients with systemic sclerosis-related interstitial lung disease. The outcomes of this research will allow us to develop personalized treatment plans for patients. All patients with systemic sclerosis-related interstitial lung disease are eligible to participate.

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS


Study Type: Observational

Details: CONQUER: Collaborative, National Quality and Efficacy Registry for Tracking Disease Progression in Systemic Sclerosis (Scleroderma)

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS


Study Type: Observational

Details: CURESSC - Consortium of Universities to REsearch Scleroderma in Southern California: This study seeks to understand the genetics of systemic sclerosis and how changes in the blood vessels and fibroblasts (cells involved in fibrosis) contribute to skin disease in systemic sclerosis. The results of this study may reveal new treatment targets. Any patient with diffuse systemic sclerosis is eligible to participate.

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS


Study Type: Observational

Details: The Gut Microbiome as a Screening Tool for ILD in Systemic Sclerosis: This study determines whether systemic sclerosis patients with interstitial lung disease (pulmonary fibrosis) have unique features of their gut microbiome. This study also seeks to determine whether the gut microbiome can be used to screen for the presence of interstitial lung disease in early systemic sclerosis.

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS


Study Type: Observational

Details: TRAUMA: Examining the prevalence of psychosocial trauma and stress in patients with Systemic Sclerosis (SSc).

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS


Study Type: Observational

Details: Scleroderma Clinical Trial Consortium: This study examines the gut microbiome of patients with systemic sclerosis from across the world to determine the impact of diet and environment on microbial composition in systemic sclerosis. This study will also evaluate whether the microbiome can serve as a marker of disease activity in systemic sclerosis.

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS


Study Type: Observational

Details: Systemic Sclerosis Microbiome study: This study examines whether the gut microbiome contributes to the pathogenesis (cause) of systemic sclerosis. All patients with systemic sclerosis are eligible to participate in this study.

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS

Upcoming Clinical Trials

Study Type: Treatment/Interventional

Details: GB44496: A study evaluating the efficacy and safety of Vixarelimab in participants with idiopathic pulmonary fibrosis and in participants with systemic sclerosis-associated interstitial lung disease.

For more information contact 310-825-9682.

Principal Investigator(s): Suzanne Kafaja, MD


Study Type: Treatment/Interventional

Details: CONQUEST: Platform clinical study for conquering scleroderma (Amlitelimab, BI 1015550, or placebo).

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS


Study Type: Treatment/Interventional

Details: DAISY: A study to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis.

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS

Upcoming Observational Studies

Study Type: Observational

Details:Investigating Molecular and Metabolic Signatures in Systemic Sclerosis

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS


Study Type: Observational

Details: USC: Role of B Cells in Systemic Sclerosis.

For more information, contact 310-794-1638.

Principal Investigator(s): Elizabeth Volkmann, MD, MS

Sjögren's Syndrome

Current Clinical Trials

We are not currently enrolling trials for this condition. Please check back for future updates.

Current Observational Studies

We are not currently enrolling observational studies for this condition. Please check back for future updates.

Upcoming Clinical Trials

There are no upcoming trials for this condition at this time. Please check back for future updates.

Upcoming Observational Studies

There are no upcoming observational studies for this condition at this time. Please check back for future updates.

Systemic Lupus Erythematosus

Current Clinical Trials

Study Type: Treatment/Interventional

Details: ITN Vibrant: A phase 2a, randomized, placebo-controlled, double-blind multicenter trial of VIB4920 for active lupus nephritis.

For more information contact 310-825-2598.

Principal Investigator(s): Maureen McMahon, MD, MS


Study Type: Treatment/Interventional

Details: Novartis CVAY736K12301: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis (SIRIUS-LN).

For more information contact 310-825-2598.

Principal Investigator(s): Maureen McMahon, MD, MS


Study Type: Treatment/Interventional

Details: Novartis CVAY736F12302: Phase 3 extension study to evaluate long-term safety of Ianalumab in participants with systemic lupus erythematosus (SIRIUS-SLE Extension). (SIRIUS-SLE LTE).

For more information, contact 310-825-2598.

Principal Investigator(s): Maureen McMahon, MD, MS


Study Type: Treatment/Interventional

Details: Poetyk: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Deucravacitinib in participants with active systemic lupus erythematosus (SLE).

For more information contact 310-825-2598.

Principal Investigator(s): Maureen McMahon, MD, MS


Study Type: Treatment/Interventional

Details: SHIELD: Effects of stopping hydroxychloroquine in elderly lupus disease.

For more information contact 310-825-2598.

Principal Investigator(s): Maureen McMahon, MD, MS

Current Observational Studies

Study Type: Observational

Details: Benlysta in Early Lupus: A study to evaluate the effects of Belimumab in patients recently diagnosed with lupus.

For more information contact 310-794-9236.

Principal Investigator(s): Maureen McMahon, MD, MS


Study Type: Observational

Details: PRiSE: Probing Remission in SLE: Blood and Brain.

For more information, contact 310-794-9236.

Principal Investigator(s): Maureen McMahon, MD, MS


Study Type: Observational

Details: Pro-inflammatory HDL Cholesterol: Evaluating biomarkers of risk for atherosclerosis in lupus. Involves a one-time blood draw.

For more information contact 310-825-2598.

Principal Investigator(s): Maureen McMahon, MD, MS

Upcoming Clinical Trials

Study Type: Treatment/Interventional

Details: Amgen: A phase 2a, open-label, multi-center, platform trial to assess the safety, tolerability, and efficacy of Inebilizumab and Blinatumomab in subjects with select autoimmune diseases.

For more information, contact 310-825-2598.

Principal Investigator(s): Maureen McMahon, MD, MS


Study Type: Treatment/Interventional

Details: Artiva: A phase 1 study to evaluate the efficacy and safety of AB-101, an allogeneic cord blood derived NK-Cell therapy in combination with B-Cell depleteing monoclonal antibodies in patients who failed treatment for class II or IV lupus nephritis.

For more information, contact 310-825-2598.

Principal Investigator(s): Jennifer Grossman, MD, PhD


Study Type: Treatment/Interventional

Details:BMS CA061-1011: A phase 2, multicenter, open-label study Of CC-97540 (BMS-986353), CD19-Targeted NEXT CAR T Cells, in participants with active SLE (including Lupus Nephritis) with inadequate response to glucocorticoids and at least two immunosuppressants (breakfree-SLE).

For more information, contact 310-825-2598.

Principal Investigator(s): Maureen McMahon, MD, MS


Study Type: Treatment/Interventional

Details: IM026-024: A study evaluating the efficacy and safety of Afimetoran compared with placebo in participants with active systemic lupus erythematosus (SLE).

For more information, contact 310-825-2598.

Principal Investigator(s): Maureen McMahon, MD, MS


Study Type: Treatment/Interventional

Details: SNAC: Systemic Lupus Erythematosus (SLE) Treatment with N-acetylcysteine (NAC) - SNAC.

For more information, contact 310-825-2598.

Principal Investigator(s): Maureen McMahon, MD, MS


Study Type: Treatment/Interventional

Details: Zenas: A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obexelimab in patients with systemic lupus erythematosus.

For more information, contact 310-825-2598.

Principal Investigator(s): Maureen McMahon, MD, MS

Upcoming Observational Studies

Study Type: Observational

Details: GSK: The evaluation Of use of Belimumab in routine care SEttings in Lupus Nephritis (LN): the OBSErve-LN study.

For more information, contact 310-825-2598.

Principal Investigator(s): Maureen McMahon, MD, MS


Study Type: Observational

Details: Lupus Landmark Study: A prospective registry and biorepository.

For more information, contact 310-825-2598.

Principal Investigator(s): Maureen McMahon, MD, MS

Vasculitis

Current Clinical Trials

We are not currently enrolling trials for this condition. Please check back for future updates.

Current Observational Studies

We are not currently enrolling studies for this condition. Please check back for future updates.

Upcoming Clinical Trials

There are no upcoming trials for this condition at this time. Please check back for future updates.

Upcoming Observational Studies

There are no upcoming studies for this condition at this time. Please check back for future updates.